Kidney function monitor company raises more capital in St. Louis

St. Louis based Medibeacon filed paperwork with the SEC last week regarding their $1.25 million raise. This brings their total raise for the year to more than $7 million. The filing identifies these raises as debt-only raises. Medibeacon has created a hardware device that helps monitory kidney function. This device, called a Transdermal GFR (Glomerular…

spn_funding-1


St. Louis based Medibeacon filed paperwork with the SEC last week regarding their $1.25 million raise.

This brings their total raise for the year to more than $7 million. The filing identifies these raises as debt-only raises.

Medibeacon has created a hardware device that helps monitory kidney function. This device, called a Transdermal GFR (Glomerular Filtration Rate), monitors the throughput and functioning of the kidney by measuring a tracer agent that is pushed out of the kidney. The company’s device monitors the rate of that ex-filtration.

According to Pitchbook, the firm has raised more than $45 million dollars over the last decade including grants, loans, and equity. Notable investors include the Missouri Technology Idea Fund, Pansend, PJM, and Jump capital.

The firm was founded by Steven Hanley and Richard Dorshow, PhD. in 2011. It has moved through a range of clinical trials, owns more than fifty patents, and continues to work with the Washington University of St. Louis School of Medicine.

For more information, check out their website at www.medibeacon.com.

JOIN THE MOVEMENT!

Sign up to receive daily updates in your inbox.